Advantaages:
- Novel therapeutic opportunities for modulating inflammation and cell trafficking
- Insights into neuroendocrine control of immune cell behavior
Summary:
This innovative technology centers around the discovery and characterization of heteromers formed between chemokine receptors (CR) and a1-adrenergic receptors (AR), specifically a1B/D-ARs. Extensive research has revealed the crucial role of these heteromeric complexes in regulating the function of CR heteromerization partners. Leveraging cutting-edge CRISPR/Cas9 gene editing, a a1B-AR knockout was successfully developed in THP-1 cells (THP-1_ADRA1BKO), leading to impaired cell migration toward ligands of CR heteromerization partners of a1B/D-AR -ARs. This novel approach opens promising avenues for therapeutic interventions to effectively modulate inflammation and cell trafficking in diverse disease processes, promising impactful advancements in medical treatment.
CRISPR/Cas9 gene editing produced the THP-1_ADRA1BKO cell line, lacking α1B-AR. The T7 surveyor assay confirmed successful gene modification. Proximity Ligation Assay (PLA) demonstrated the absence of α1B-AR in THP-1_ADRA1BKO cells. Chemotaxis experiments revealed altered responses in THP-1_ADRA1BKO cells compared to wild-type THP-1 cells when exposed to CCL23, CCL2, CCL1, and CXCL12. The study highlights the importance of α1B/D-adrenergic receptors in mediating chemotactic responses and their potential as drug targets for modulating inflammation and cell trafficking.
Desired Partnerships:
- License
- Sponsored Research
- Co-Development